Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: A systematic review and network meta-analysis

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Sun, Feng ^a,b   Chai, Sanbao ^c   Li, Lishi ^a,d   Yu, Kai ^e   Yang, Zhirong ^a,f   Wu, Shanshan ^a   Zhang, Yuan ^a   Ji, Linong ^g   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHIHEZI UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^f SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; PEPTIDE; VENOM;

DRUG EFFICACY; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; METABOLISM; OBESITY; OVERWEIGHT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; OBESITY; OVERWEIGHT; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; VENOMS; WEIGHT LOSS;

EID: 84922380651     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/157201     Document Type: Review

References (35)

1. M. E. Doyle and J. M. Egan, "Mechanisms of action of glucagonlike peptide 1 in the pancreas", Pharmacology & Therapeutics, vol. 113, no. 3, pp. 546-593, 2007.
2. J. J. Holst, "The physiology of glucagon-like peptide 1", Physiological Reviews, vol. 87, no. 4, pp. 1409-1439, 2007.
3. D. S. Shyangdan, P. L. Royle, C. Clar, P. Sharma, and N. R. Waugh, "Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis", BMC Endocrine Disorders, vol. 10, article 20, 2010.
4. M. S. Fineman, B. B. Cirincione, D. Maggs, and M. Diamant, "GLP-1 based therapies: differential effects on fasting and postprandial glucose", Diabetes, Obesity and Metabolism, vol. 14, no. 8, pp. 675-688, 2012.
5. D. J. Drucker and M. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
6. M. Tzefos, K. Harris, and A. Brackett, "Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults", Annals of Pharmacotherapy, vol. 46, no. 1, pp. 68-78, 2012.
7. B. Zinman, W. E. Schmidt, A. Moses, N. Lund, and S. Gough, "Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme", Diabetes, Obesity & Metabolism, vol. 14, no. 1, pp. 77-82, 2012.
8. D. Russell-Jones and R. Khan, "Insulin-associated weight gain in diabetes-causes, effects and coping strategies", Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 799-812, 2007.
9. B. Verges, C. Bonnard, and E. Renard, "Beyond glucoselowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system", Diabetes & Metabolism, vol. 37, no. 6, pp. 477-488, 2011.
10. S. E. Kanoski, L. E. Rupprecht, S. M. Fortin, B. C. De Jonghe, and M. R. Hayes, "The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide", Neuropharmacology, vol. 62, no. 5-6, pp. 1916-1927, 2012.
11. L. E. Robinson, T. A. Holt, K. Rees, H. S. Randeva, and J. P. O'Hare, "Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and metaanalysis", BMJ Open, vol. 3, no. 1, Article ID e001986, 2013.
12. M. Katout, H. Zhu, J. Rutsky et al., "Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and metaregression", American Journal of Hypertension, vol. 27, no. 1, pp. 130-139, 2014.
13. T. Vilsbøll, M. Christensen, A. E. Junker, F. K. Knop, and L. L. Gluud, "Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials", British Medical Journal, vol. 344, no. 7841, Article ID d7771, 2012.
14. G. Van Valkenhoef, G. Lu, B. De Brock, H. Hillege, A. E. Ades, and N. J. Welton, "Automating network meta-analysis", Research Synthesis Methods, vol. 3, no. 4, pp. 285-299, 2012.
15. A. R. Jadad, R. A. Moore, D. Carroll et al., "Assessing thequality of reports of randomized clinical trials: is blinding necessary?" Controlled Clinical Trials, vol. 17, no. 1, pp. 1-12, 1996.
16. R. Der Simonian and N. Laird, "Meta-analysis in clinical trials", Controlled Clinical Trials, vol. 7, no. 3, pp. 177-188, 1986.
17. J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis", Statistics in Medicine, vol. 21, no. 11, pp. 1539-1558, 2002.
18. G. Lu and A. E. Ades, "Combination of direct and indirect evidence in mixed treatment comparisons", Statistics in Medicine, vol. 23, no. 20, pp. 3105-3124, 2004.
19. D. J. Spiegelhalter, N. G. Best, B. P. Carlin, and A. Van Der Linde, "Bayesian measures of model complexity andfit", Journal of the Royal Statistical Society Series B: Statistical Methodology, vol. 64, no. 4, pp. 583-639, 2002.
20. G. Salanti, A. E. Ades, and J. P. A. Ioannidis, "Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial", Journal of Clinical Epidemiology, vol. 64, no. 2, pp. 163-171, 2011.
21. A. Chaimani, J. P. T. Higgins, D. Mavridis, P. Spyridonos, and G. Salanti, "Graphical tools for network meta-analysis in STATA", PLoS ONE, vol. 8, no. 10, Article ID e76654, 2013.
22. A. A. Veroniki, H. S. Vasiliadis, J. P. Higgins, and G. Salanti, "Evaluation of inconsistency in networks of interventions", International Journal of Epidemiology, vol. 42, no. 1, pp. 332-345, 2013.
23. J. B. Buse, M. Nauck, T. Forst et al., "Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study", The Lancet, vol. 381, no. 9861, pp. 117-124, 2013.
24. J. B. Buse, J. Rosenstock, G. Sesti et al., "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)", The Lancet, vol. 374, no. 9683, pp. 39-47, 2009.
25. C. A. Maggio and F. X. Pi-Sunyer, "Obesity and type 2 diabetes", Endocrinology Metabolism Clinics of North America, vol. 32, no. 4, pp. 805-822, 2003.
26. G. A. Bray, "Medical consequences of obesity", The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2583-2589, 2004.
27. S.-J. Shin, "Glucagon-like peptide-1 receptor agonists and their effects on weight reduction", Journal of Diabetes Investigation, vol. 3, no. 6, pp. 490-491, 2012.
28. O. J. Phung, J. M. Scholle, M. Talwar, and C. I. Coleman, "Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes", The Journal of the American Medical Association, vol. 303, no. 14, pp. 1410-1418, 2010.
29. K. Niswender, X. Pi-Sunyer, J. Buse et al., "Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme", Diabetes, Obesity and Metabolism, vol. 15, no. 1, pp. 42-54, 2013.
30. M. Marre, J. Shaw, M. Brandle et al., "Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)", Diabetic Medicine, vol. 26, no. 3, pp. 268-278, 2009.
31. B. Zinman, J. Gerich, J. B. Buse et al., "Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)", Diabetes Care, vol. 32, no. 7, pp. 1224-1230, 2009.
32. B. Zinman, J. Gerich, J. B. Buse et al., "Erratum in 'Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)'", Diabetes Care, vol. 33, no. 3, p. 692, 2010.
33. M. Nauck, A. Frid, K. Hermansen et al., "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes", Diabetes Care, vol. 32, no. 1, pp. 84-90, 2009.
34. P. J. Larsen, "Mechanisms behind GLP-1 induced weight loss", The British Journal of Diabetes & Vascular Disease, vol. 8, no. 2, supplement, pp. S34-S41, 2008.
35. B. McIntosh, C. Cameron, S. R. Singh et al., "Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixedtreatment comparison meta-analysis", Open Medicine, vol. 5, no. 1, pp. e35-e48, 2011.